Evidence map›Paper›PMID 39400818›Full record

ArticleAdvances in experimental medicine and biology2024

Preventing Fluid Retention After Subarachnoid Haemorrhage During Administration of Endothelin Receptor Antagonist.

Yu Okuma, Shinobu Hirahata, Akane Tanda, Kazumoto Suzuki, Kentaro Shimoda, Goro Kido, Yukihide Kagawa

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yu OkumaDepartment of Neurological Surgery, Sonoda Daiichi Hospital, Tokyo, Japan.
Shinobu HirahataDepartment of Neurological Surgery, Sonoda Daiichi Hospital, Tokyo, Japan.
Akane TandaDepartment of Neurological Surgery, Sonoda Daiichi Hospital, Tokyo, Japan.
Kazumoto SuzukiDepartment of Neurological Surgery, Sonoda Daiichi Hospital, Tokyo, Japan.
Kentaro ShimodaDepartment of Neurological Surgery, Sonoda Daiichi Hospital, Tokyo, Japan.
Goro KidoDepartment of Neurological Surgery, Sonoda Daiichi Hospital, Tokyo, Japan.
Yukihide KagawaDepartment of Neurological Surgery, Sonoda Daiichi Hospital, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prevention of delayed cerebral infarction (DCI) due to cerebral vasospasm after subarachnoid haemorrhage (SAH) has been done with intravenous Rho kinase inhibitors (ROCKI), ozagrel sodium (TXA2I), selective ROCKI infusion (ROCKI i.a.), and cerebrospinal fluid (CSF) drainage. The endothelin receptor antagonist (ERA, clazosentan) became available in 2022 and is said to be highly recommended for DCI prevention, while fluid retention such as pleural effusion and pulmonary oedema accumulation is often experienced. We investigated the relationship between patient background, fluid retention, and ERA. Ten consecutive SAH patients treated with ERA from July to December 2022 were included. We examined the results of blood sampling on admission, echocardiography, chest computed tomography (CT), with postoperative DCI, and hydrocephalus requiring cerebrospinal fluid shunt (hydro), and symptomatic fluid retention requiring albumin and furosemide (third fluid space). Two males and eight females, mean age 63 years, mean preoperative World Federation Neurosurgical Surgeons (WFNS) grade 3.5, mean creatinine 0.94, mean brain natriuretic peptide (NT-proBNP). In 1883, two patients with Takotsubo cardiomyopathy and four patients with neurogenic pulmonary oedema are present. All patients underwent coil embolisation, and postoperative CSF drainage, ROCKI, TXA2I systemic administration, and ROCKI i.a. There were one DCI, three hydro, and five third fluid cases. Concerning the third fluid, the only significant difference was found in the age. An improvement in fluid retention after ERA discontinuation in old patients was shown. Our experience suggests that age may be the most influential factor. Based on these results, we have also found that by avoiding the use of ERA in patients older than 80 years, strictly limiting the infusion volume when using ERA, and actively using the drugs for heart failure early on, the frequency of suffering from third fluid space is reduced.

Indexed as

Endothelin Receptor AntagonistsPyridinesSubarachnoid HemorrhageAdultAgedCerebral InfarctionDioxanesFemaleHumansHydrocephalusMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsPulmonary EdemaPyrimidinesclazosentanDioxanesEndothelin Receptor AntagonistsNatriuretic Peptide, BrainPeptide FragmentsPyridinesPyrimidinesSulfonamidesTetrazolesCerebral vasospasmEndothelin receptor antagonist (ERA)Fluid retentionSelective Rho kinase inhibitors infusion (ROCKI i.a.)Subarachnoid haemorrhage

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.